# Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study

> **NCT02623062** · PHASE3 · COMPLETED · sponsor: **Reckitt Benckiser Healthcare (UK) Limited** · enrollment: 644 (actual)

## Conditions studied

- Gastro-esophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** Compound Sodium Alginate Oral Suspension sachet
- **DRUG:** Matched placebo

## Key facts

- **NCT ID:** NCT02623062
- **Lead sponsor:** Reckitt Benckiser Healthcare (UK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-05
- **Target enrollment:** 644 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623062, "Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02623062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*